<DOC>
	<DOCNO>NCT01568099</DOCNO>
	<brief_summary>This phase I study assess tolerability safety 4 injection two different dos AFFITOPE® PD01A formulate adjuvant patient early Parkinson 's disease male female patient age 45 65 year ( age 40 45 year evidence genetic form disease diagnosis idiopathic Parkinson 's disease confirm , approval Sponsor ) . One study site Vienna ( Austria ) involve . Each patient 's participation last 1 year . In addition , 8 patient offer participation within untreated control group .</brief_summary>
	<brief_title>Tolerability Safety Subcutaneous Administration Two Doses AFFITOPE® PD01A Early Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Informed consent capability Early PD ( ≤ 4 year ) , Hoehn &amp; Yahr Stages I/II fulfill UK Parkinson 's Disease Society Brain Bank Criteria Brain magnetic resonance imaging ( MRI ) scan DATSPECT scan consistent diagnosis PD Age 45 65 year age 40 45 year evidence genetic form disease diagnosis idiopathic PD confirm , approval Sponsor Caregiver able attend visit patient Stable dos medication ( levodopa ( +/ benserazide , carbidopa ) , COMT inhibitor ( entacapone , tolcapone ) , nonergot dopamine agonist ( pramipexol , ropinirol , rotigotine ) , MAOB inhibitor rasagiline amantadine allow ) Women childbearing potential without birth control pregnant woman Participation another clinical trial Autoimmune disease allergy component vaccine Contraindications MRI , DATSPECT , colonoscopy include biopsy lumbar puncture Dementia History cancer ( Exceptions : basal cell carcinoma , intraepithelial cervical neoplasia ) Active infectious disease Immunodeficiency Significant systemic illness psychiatric illness Parkinsonlike disease secondary drug therapy side effect Parkinsonplus syndrome Heredodegenerative disorder Alcoholism substance abuse Prior treatment experimental immunotherapeutics PD include IVIG , immunosuppressive drug treatment deep brain stimulation Venous status render impossible place i.v . access</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>